Monte Rosa Therapeutics (GLUE) Leases (2023 - 2025)
Historic Leases for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $25.1 million.
- Monte Rosa Therapeutics' Leases fell 840.15% to $25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.1 million, marking a year-over-year decrease of 840.15%. This contributed to the annual value of $26.8 million for FY2024, which is 686.27% down from last year.
- Monte Rosa Therapeutics' Leases amounted to $25.1 million in Q3 2025, which was down 840.15% from $25.7 million recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' Leases registered a high of $30.5 million during Q1 2023, and its lowest value of $25.1 million during Q3 2025.
- Over the past 3 years, Monte Rosa Therapeutics' median Leases value was $27.9 million (recorded in 2024), while the average stood at $27.9 million.
- As far as peak fluctuations go, Monte Rosa Therapeutics' Leases tumbled by 686.27% in 2024, and later plummeted by 840.15% in 2025.
- Monte Rosa Therapeutics' Leases (Quarter) stood at $28.8 million in 2023, then dropped by 6.86% to $26.8 million in 2024, then decreased by 6.58% to $25.1 million in 2025.
- Its Leases stands at $25.1 million for Q3 2025, versus $25.7 million for Q2 2025 and $26.3 million for Q1 2025.